

Print selected from Online session02/10/2002

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

Print selected from Online session02/10/2002

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:43:46 ON 02 OCT 2002

| | | |
|----------------------|------------|---------|
| => file registry | SINCE FILE | TOTAL |
| COST IN U.S. DOLLARS | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 15:43:54 ON 02 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2002 HIGHEST RN 457857-22-6
DICTIONARY FILE UPDATES: 1 OCT 2002 HIGHEST RN 457857-22-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s omneprazole/cn
L1 0 OMNEPRAZOLE/CN

=> s pantoprazole/cn
L2 1 PANTOPRAZOLE/CN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 102625-70-7 REGISTRY
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(Difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
CN BY 1023
CN Pantoprazole
CN SKF 96022
FS 3D CONCORD
DR 154644-14-1
MF C16 H15 F2 N3 O4 S
CI COM
SR CA


Print selected from Online session15:52Page 2

Print selected from Online session 02/10/2002

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

338 REFERENCES IN FILE CA (1962 TO DATE)
11 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
339 REFERENCES IN FILE CAPLUS (1962 TO DATE)

```
=> s omeprazole
L3      17 OMEPRAZOLE

=> s omeprazole/cn
L4      1 OMEPRAZOLE/CN

=> d
```

```
L4  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2002 ACS
RN  73590-58-6  REGISTRY
CN  1H-Benzimidazole, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-
    pyridinyl)methylsulfinyl]- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN  (.+-.)-Omeprazole
CN  2-[(3,5-Dimethyl-4-methoxy-2-pyridyl)methylsulfinyl]-5-methoxy-1H-
    benzimidazole
CN  Acidex
CN  Antra
CN  Antra MUPS
CN  Audazol
CN  Aulcer
CN  Belmazol
CN  Ceprandal
CN  Desec
CN  Dizprazol
CN  Dudencer
CN  Elgam
CN  Emeproton
CN  Epirazole
CN  Gastrimut
CN  Gastroloc
CN  Gastrozole
CN  Gibancer
CN  H 168/68
```

Print selected from Online session02/10/2002

CN Indurgen
CN Inhibitron
CN Inhipump
CN Logastric
CN Lomac
CN Losec
CN Miol
CN Miracid
CN Mopral
CN Ocid
CN Omapren
CN Omebeta 20
CN Omed
CN Omedar
CN OMEP
CN Omepral
CN **Omeprazole**
CN Omeprazon
CN Omepril
CN Omezol
CN Omezzol
CN Omid
CN Omisec
CN Omizac
CN OMP
CN Ompanyt
CN OMZ
CN Oprax
CN Opraz
CN Ozoken

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

FS 3D CONCORD

DR 172964-80-6, 131959-78-9


MF C17 H19 N3 O3 S

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
CEN, CHEMCATS, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGNL, DRUGPAT,
DRUGU, DRUGUPDATES, EMBASE, HSDB*, IPA, MEDLINE, MRCK*, PHAR,
PHARMASEARCH, PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2,
USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2209 REFERENCES IN FILE CA (1962 TO DATE)

~ 41 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

Print selected from Online session02/10/2002

2215 REFERENCES IN FILE CAPLUS (1962 TO DATE)

| => file uspatall
COST IN U.S. DOLLARS | SINCE FILE
ENTRY | TOTAL
SESSION |
|------------------------------------------|---------------------|------------------|
| FULL ESTIMATED COST | 21.06 | 21.27 |

FILE 'USPATFULL' ENTERED AT 15:46:45 ON 02 OCT 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:46:45 ON 02 OCT 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> d his

(FILE 'HOME' ENTERED AT 15:43:46 ON 02 OCT 2002)

FILE 'REGISTRY' ENTERED AT 15:43:54 ON 02 OCT 2002

| | |
|----|---------------------|
| L1 | 0 S OMNEPRAZOLE/CN |
| L2 | 1 S PANTOPRAZOLE/CN |
| L3 | 17 S OMEPRAZOLE |
| L4 | 1 S OMEPRAZOLE/CN |

FILE 'USPATFULL, USPAT2' ENTERED AT 15:46:45 ON 02 OCT 2002

=> s 14 and (blood plasma profile or extended release)
L5 8 L4 AND (BLOOD PLASMA PROFILE OR EXTENDED RELEASE)

=> d abs bib hitstr 1-8

L5 ANSWER 1 OF 8 USPATFULL

AB In one embodiment, the invention relates to sustained-release compositions comprising one or more prolamins, one or more gelling agents, and one or more active agents. Such compositions are particularly useful for controlled delivery of high solubility and/or high dosage active agents. In another embodiment, the present invention relates to delayed-onset compositions comprising a dry coating comprising one or more prolamins and one or more gelling agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:198314 USPATFULL

TI Prolamin-based sustained-release compositions and delayed-onset compositions

IN Bacon, Johnatan, Montreal, CANADA
Desjardins, Alain, Montreal, CANADA

PI US 2002106408 A1 20020808

AI US 2000-728840 A1 20001201 (9)

DT Utility

FS APPLICATION

LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 7 Drawing Page(s)


LN.CNT 936

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 73590-58-6, Omeprazole
(prolamin-based sustained-release compns. and delayed-onset compns.)

RN 73590-58-6 USPATFULL

CN 1H-Benzimidazole, 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 8 USPATFULL

AB An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:69628 USPATFULL

TI Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID

IN Depui, Helene, Goteborg, SWEDEN
Lundberg, Per, Molndal, SWEDEN

PA AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)

PI US 6365184 B1 20020402

AI US 1999-471958 19991223 (9)

RLI Continuation of Ser. No. US 793078, now abandoned

PRAI SE 1996-70 19960108

DT Utility

FS GRANTED

EXNAM Primary Examiner: Dudash, Diana; Assistant Examiner: Sharareh, Shahnam

LREP White & Case LLP

CLMN Number of Claims: 34

ECL Exemplary Claim: 1

DRWN 6 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 1319


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 73590-58-6, Omeprazole

(oral pharmaceuticals contg. proton pump inhibitor and NSAID)

RN 73590-58-6 USPATFULL

CN 1H-Benzimidazole, 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



Print selected from Online session02/10/2002

L5 ANSWER 3 OF 8 USPATFULL

AB The present invention is related to an effervescent pharmaceutical preparation comprising effervescent excipients and a plurality of individual units comprising a pharmaceutically active compound and optional excipients wherein the units (1) are provided with a floating generating system. The floating generating systems comprises at least two coating layers, one of which is a gas generating layer (2) and the other layer is a barrier layer (3) enclosing the generated gas. Furthermore the invention is related to a process for the manufacture of the dosage forms, and their use in medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:147489 USPATFULL

TI Multiple unit effervescent dosage form

IN Lundberg, Per Johan, Molndal, Sweden
Thune, Mikael, Molndal, Sweden

PA AstraZeneca AB, Sodertalje, Sweden (non-U.S. corporation)

PI US 6284271 B1 20010904

WO 9901112 19990114

AI US 1998-125933 19980828 (9)

WO 1998-SE1209 19980622

19980828 PCT 371 date

19980828 PCT 102(e) date

PRAI SE 1997-2533 19970701

DT Utility

FS GRANTED

EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Fubara, Blessing

LREP White & Case LLP

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN 4 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 725


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 73590-58-6, Omeprazole

(multiple unit effervescent dosage forms)

RN 73590-58-6 USPATFULL

CN 1H-Benzimidazole, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 8 USPATFULL


AB A new administration regimen giving an extended plasma concentration profile of a H.^{sup.+}, K.^{sup.+}-ATPase inhibitor. The extended plasma profile is received by two or more consecutive administrations of a unit dose of a H.^{sup.+}, K.^{sup.+}-ATPase with 0.5-4 hours interval or by a pharmaceutical composition with **extended release**, which may be administered once daily.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AN 2001:114635 USPATFULL

Print selected from Online session02/10/2002

TI ADMINISTRATION OF PHARMACEUTICALS
IN CEDERBERG, CHRISTER, MOLNDAL, Sweden
SACHS, GEORGE, ENCINO, CA, United States
PI US 2001008900 A1 20010719
AI US 1997-945425 A1 19971021 (8)
WO 1997-SE1098 19970618
None PCT 102(e) date
PRAI SE 1996-2442 19960620
DT Utility
FS APPLICATION
LREP WHITE & CASE LLP, PATENT DEPARTMENT, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 355
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 73590-58-6, Omeprazole 73590-58-6D, Omeprazole, alk.
salts and enantiomers
(administration regimen of H+, K+ATPase inhibitors)
RN 73590-58-6 USPATFULL
CN 1H-Benzimidazole, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 73590-58-6 USPATFULL
CN 1H-Benzimidazole, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 8 USPATFULL

AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and

Print selected from Online session02/10/2002

triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:93131 USPATFULL

TI Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

IN Patel, Mahesh V., Salt Lake City, UT, United States

Chen, Feng-Jing, Salt Lake City, UT, United States

PA Lipocene, Inc., Salt Lake City, UT, United States (U.S. corporation)

PI US 6248363 B1 20010619

AI US 1999-447690 19991123 (9)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Spear, James M.

LREP Reed, Dianne E. Reed & Associates

CLMN Number of Claims: 57

ECL Exemplary Claim: 1

DRWN 4 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 3302


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 73590-58-6, Omeprazole

(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

RN 73590-58-6 USPATFULL

CN 1H-Benzimidazole, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 8 USPATFULL

AB An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more antibacterial compounds in a fixed formulation. The fixed formulation is intended for oral use and in the form of an enteric coating layered tablet, an capsule or a multiple unit tableted dosage form. The multiple unit dosage form is most preferred. The new fixed formulation is especially useful in the treatment of disorders associated with Helicobacter infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:141911 USPATFULL

TI Oral pharmaceutical dosage form

IN Depui, Helene, Goteborg, Sweden

Rosinski, Adam, Molndal, Sweden

PA Astra Aktiebolag, Sodertalje, Sweden (non-U.S. corporation)

PI US 6136344 20001024

WO 9624375 19960815

AI US 1996-628712 19960415 (8)

WO 1996-SE125 19960202

19960415 PCT 371 date
19960415 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1995-464775, filed on 7 Jun 1995,
now abandoned

PRAI SE 1995-422 19950206

DT Utility

FS Granted

EXNAM Primary Examiner: Kishore, Gollamudi S.

LREP White & Case LLP

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN 4 Drawing Figure(s); 1 Drawing Page(s)


LN.CNT 1271

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 73590-58-6, Omeprazole
(oral multiple unit pharmaceutical dosage forms)

RN 73590-58-6 USPATFULL

CN 1H-Benzimidazole, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 8 USPATFULL

AB An oral pharmaceutical dosage form comprising a proton pump inhibitor and one or more prokinetic agents in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of multilayered tablets, capsules or multiple unit tableted dosage forms. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of disorders associated with gastro oesophageal reflux diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:137861 USPATFULL

TI Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent

IN Depui, Helene, Goteborg, Sweden

Hallgren, Agneta, Molndal, Sweden

PA AstraZeneca AB, Sodertalje, Sweden (non-U.S. corporation)

PI US 6132771 20001017

WO 9725065 19970717

AI US 1997-750936 19970213 (8)

WO 1996-SE1736 19961220

19970213 PCT 371 date

19970213 PCT 102(e) date

PRAI SE 1996-72 19960108

DT Utility

FS Granted

EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Seidleck, Brian K

LREP White & Case LLP

Print selected from Online session02/10/2002

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 4 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 1165


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 73590-58-6, Omeprazole

(oral pharmaceutical dosage forms comprising proton pump inhibitor and prokinetic agent for gastroesophageal reflux treatment)

RN 73590-58-6 USPATFULL

CN 1H-Benzimidazole, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 8 USPATFULL

AB The present invention deals with a pharmaceutical product in unit dosage form and a unit dosage drug delivery system which comprises a multiple layer capsule or housing having two or more layers, the layers being of materials, wherein the outer layer possesses a hydrophilic character and the inner layer possesses a hydrophobic character, and a capsule filling wherein one or more drug substances are admixed, dissolved, suspended or agglomerated in a hydrophobic support.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:118864 USPATFULL

TI Drug delivery system

IN Veronesi, Paolo Alberto, Milan, Italy

PA Therapicon S.R.L., Milan, Italy (non-U.S. corporation)

PI US 5814338 19980929

WO 9601612 19960125

AI US 1997-765952 19970109 (8)

WO 1995-EP2488 19950624

19970109 PCT 371 date

19970109 PCT 102(e) date

PRAI GB 1994-13951 19940711

DT Utility

FS Granted

EXNAM Primary Examiner: Schofer, Joseph L.; Assistant Examiner: Shelborne, Kathryn E.

LREP Shurtz, Steven P. Brinks Hofer Gilson & Lione

CLMN Number of Claims: 48

ECL Exemplary Claim: 1

DRWN 4 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 1363


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 73590-58-6, Omeprazole

(hydrophobic and hydrophilic multiple layered capsules for drugs)

RN 73590-58-6 USPATFULL

CN 1H-Benzimidazole, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 15:43:46 ON 02 OCT 2002)

FILE 'REGISTRY' ENTERED AT 15:43:54 ON 02 OCT 2002

L1 0 S OMNEPRAZOLE/CN
L2 1 S PANTOPRAZOLE/CN
L3 17 S OMEPRAZOLE
L4 1 S OMEPRAZOLE/CN

FILE 'USPATFULL, USPAT2' ENTERED AT 15:46:45 ON 02 OCT 2002


L5 8 S L4 AND (BLOOD PLASMA PROFILE OR EXTENDED RELEASE)

=> s 12 and (extended release or blood plasma profile)

L6 4 L2 AND (EXTENDED RELEASE OR BLOOD PLASMA PROFILE)

=> d 1-4 hitstr bib abs

L6 ANSWER 1 OF 4 USPATFULL
IT 102625-70-7, Pantoprazole
(oral pharmaceuticals contg. proton pump inhibitor and NSAID)
RN 102625-70-7 USPATFULL
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



AN 2002:69628 USPATFULL
TI Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
IN Depui, Helene, Goteborg, SWEDEN
Lundberg, Per, Molndal, SWEDEN
PA AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI US 6365184 B1 20020402
AI US 1999-471958 19991223 (9)
RLI Continuation of Ser. No. US 793078, now abandoned
PRAI SE 1996-70 19960108
DT Utility
FS GRANTED
EXNAM Primary Examiner: Dudash, Diana; Assistant Examiner: Sharareh, Shahnam
LREP White & Case LLP

Print selected from Online session02/10/2002

CLMN Number of Claims: 34

ECL Exemplary Claim: 1

DRWN 6 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 1319

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


L6 ANSWER 2 OF 4 USPATFULL

IT 102625-70-7, Pantoprazole

(oral compns. contg. antimicrobial actives and sustained-release pantoprazole)

RN 102625-70-7 USPATFULL

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



AN 2001:130895 USPATFULL

TI Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole

IN Sachs, George, Encino, CA, United States

Dietrich, Rango, Constance, Germany, Federal Republic of

PA BYK Gulden Lomberg Chemische Fabrik GmbH, Constance, Germany, Federal Republic of (non-U.S. corporation)

PI US 6274173 B1 20010814

AI US 1999-461388 19991215 (9)

RLI Continuation of Ser. No. US 1998-42090, filed on 13 Mar 1998, now patented, Pat. No. US 6068856 Division of Ser. No. US 1995-498386, filed on 5 Jul 1995, now patented, Pat. No. US 5945124

DT Utility

FS GRANTED

EXNAM Primary Examiner: Spear, James M.

LREP Jacobson Holman, PLLC

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 509

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An oral pharmaceutical composition comprises an acid-labile irreversible proton pump inhibitor in pellet or tablet form, wherein the irreversible proton pump inhibitor is at least partly in slow-release form. On combined administration with an anti-microbiially-active ingredient, the composition is distinguished by imparting an enhanced action of rapid

Print selected from Online session02/10/2002

onset against disorders caused by Helicobacter.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


L6 ANSWER 3 OF 4 USPATFULL

IT 102625-70-7, Pantoprazole

(oral compns. contg. antimicrobial actives and sustained-release pantoprazole)

RN 102625-70-7 USPATFULL

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



AN 2000:67447 USPATFULL

TI Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole

IN Sachs, George, Encino, CA, United States

Dietrich, Rango, Constance, Germany, Federal Republic of

PA BYK Gulden Chemische Fabrik GmbH, Constance, Germany, Federal Republic of (non-U.S. corporation)

PI US 6068856 20000530

AI US 1998-42090 19980313 (9)

RLI Division of Ser. No. US 1995-498386, filed on 5 Jul 1995, now patented, Pat. No. US 5945124

DT Utility

FS Granted

EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Spear, James M.

LREP Jacobson, Price, Holman & Stern, PLLC

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 497

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An oral pharmaceutical composition of pantoprazole in pellet or tablet form, wherein the pantoprazole is at least partly in slow-release form, is distinguished, on combined administration with an antimicrobially-active ingredient, by an enhanced action of rapid onset against disorders caused by Helicobacter.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


L6 ANSWER 4 OF 4 USPATFULL

IT 102625-70-7, Pantoprazole

(oral compns. contg. antimicrobial actives and sustained-release pantoprazole)

RN 102625-70-7 USPATFULL

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



AN 1999:102514 USPATFULL
TI Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
IN Sachs, George, Encino, CA, United States
Dietrich, Rango, Constance, Germany, Federal Republic of
PA BYK Gulden Chemische Fabrik GmbH, Constance, Germany, Federal Republic of (non-U.S. corporation)
PI US 5945124 19990831
AI US 1995-498386 19950705 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Spear, James M.
LREP Jacobson, Price, Holman & Stern, PLLC
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An oral pharmaceutical composition of pantoprazole in pellet or tablet form, wherein the pantoprazole is at least partly in slow-release form, is distinguished, on combined administration with an antimicrobially-active ingredient, by an enhanced action of rapid onset against disorders caused by Helicobacter.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.